Cargando…
Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study
BACKGROUND: Immune checkpoint inhibitors (ICIs) have become a standard of care for various tumor types. Their unique spectrum of side effects demands continuous and long-lasting assessment of symptoms. Electronic patient-reported outcome (ePRO) follow-up has been shown to improve survival and qualit...
Autores principales: | Iivanainen, Sanna, Alanko, Tuomo, Vihinen, Pia, Konkola, Teemu, Ekstrom, Jussi, Virtanen, Henri, Koivunen, Jussi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657724/ https://www.ncbi.nlm.nih.gov/pubmed/33112242 http://dx.doi.org/10.2196/17898 |
Ejemplares similares
-
ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study
por: Iivanainen, Sanna, et al.
Publicado: (2019) -
Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies
por: Iivanainen, Sanna, et al.
Publicado: (2021) -
ePRO symptom follow-up of colorectal cancer patients receiving oxaliplatin-based adjuvant chemotherapy is feasible and enhances the quality of patient care: a prospective multicenter study
por: Iivanainen, Sanna, et al.
Publicado: (2023) -
Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers
por: Tikkanen, Antti, et al.
Publicado: (2020) -
Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection
por: Iivanainen, Sanna, et al.
Publicado: (2020)